| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
| [0153]
|
| An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
| [0153]
|
| The hallmarks of cancer
| [0153]
|
| Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF
| [0153]
|
| Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization
| [0153]
|
| Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
| [0153]
|
| Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
| [0153]
|
| Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
| [0153]
|
| Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma
| [0153]
|
| Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
| [0153]
|